CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 21 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
Nicotine 7 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01223404
NCT01223404N/ACompleted

Nicotinic Modulation of the Default Network of Resting Brain Function

University of Maryland, Baltimore·interventional·Posted Oct 19, 2010·Updated Aug 19, 2019

In Brief

A clinical study evaluating Placebo, Nicotine, and 1 other intervention for Magnetic Resonance Imaging and 3 related conditions. Completed, enrolled 21 participants across 2 sites.

Detailed Summary

Many disorders where attentional problems are a hallmark, such as Alzheimer's disease and schizophrenia, display abnormal regulation of the so-called default network of resting brain function that maintains internally directed thought when the mind is free to wander. There is indication that nicotine may improve attention by aiding the deactivation of the default network, and this mechanism may be of therapeutic benefit for the above disease states. The current project aims at providing a proof of concept by demonstrating that nicotinic drugs modulate default network function. The nicotinic agonist nicotine is hypothesized to improve attention by facilitating the down-regulation of default network activity, and the nicotinic antagonist mecamylamine is hypothesized to impair attention by impeding the down-regulation of default network activity during attentional task performance.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 19, 2010
Enrollment StartOct 1, 2010
Primary CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 15.7 years ago

Interventions

Placebodrug

Participants are administered a placebo patch and a placebo capsule

Nicotinedrug

Participants are administered a nicotine patch (7 mg/24 hrs) and a placebo capsule

Mecamylaminedrug

Participants are administered a placebo patch and a capsule containing 7.5 mg of mecamylamine